Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Os, R.
Right arrow Articles by Mauch, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Os, R.
Right arrow Articles by Mauch, P. M.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Host conditioning with 5-fluorouracil and kit-ligand to provide for long-term bone marrow engraftment

R van Os, D Dawes, JM Mislow, A Witsell and PM Mauch

Department of Radiation Oncology, Harvard Medical School, Boston, MA 02215, USA.

Administration of kit-ligand (KL) before and after doses of 5- fluorouracil (5-FU) results in marrow failure in mice, presumably because of enhanced KL-induced cycling of stem cells, which makes them more susceptible to the effects of 5-FU. In attempt to capitalize on this effect on stem cells, we studied the ability of KL and 5-FU to allow stable donor engraftment of congenically marked marrow in a C57BL/6 (B6) mouse model. KL was administered subcutaneously at 50 microg/kg, 21 hours and 9 hours before and 3 hours after each of two doses of 5-FU (125 mg/kg) given 7 days apart to B6-recipients. Animals then received three injections of 10(7) congenic B6-Gpi-1a-donor bone marrow cells at 24, 48, and 72 hours after the second 5-FU dose. A separate group of animals received a single dose of either 1 x 10(7) or 3 x 10(7) donor marrow cells 24 hours after the last 5-FU dose. The level of engraftment was measured from Gpi-phenotyping at 1, 3, 6, and 8 months in red blood cells (RBCs) and at 8 months by phenotyping cells from the thymus, spleen, and marrow. Percent donor engraftment in RBCs appeared stable after 6 months. The percent donor engraftment in RBCs at 8 months was significantly higher in KL + 5-FU prepared recipients (33.0 +/- 2.7), compared with 5-FU alone (18.5 +/- 2.6, P < .0005), or saline controls (17.8 +/- 1.7, P < .0001). In an additional experiment, granulocyte colony-stimulating factor (100 microg/dose) was added to a reduced dose of KL (12.5 microg/dose); engraftment was similar to KL alone. At 8 months after transplantation the levels of engraftment in other tissues such as bone marrow, spleen, and thymus correlated well with erythroid engraftment to suggest that multipotent long-term repopulating stem cells had engrafted in these animals. There are concerns for the toxicity of total body irradiation (TBI)- or busulfan- based regimens in young recipients of syngeneic or transduced autologous marrow who are transplanted for correction of genetic disease. In these recipients complete donor engraftment may not be needed. The results with KL and 5-FU are encouraging for the further refinement of non-TBI, nonbusulfan techniques to achieve stable mixed chimerism.

Volume 89, Issue 7, pp. 2376-2383, 04/01/1997
Copyright © 1997 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
G. A. Velders, R. van Os, H. Hagoort, P. Verzaal, H. F. L. Guiot, I. J. D. Lindley, R. Willemze, G. Opdenakker, and W. E. Fibbe
Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization
Blood, January 1, 2004; 103(1): 340 - 346.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. L. Bradley, T. S. Hawley, and K. D. Bunting
Cell intrinsic defects in cytokine responsiveness of STAT5-deficient hematopoietic stem cells
Blood, December 1, 2002; 100(12): 3983 - 3989.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. J. K. Noach, A. Ausema, J. H. Dillingh, B. Dontje, E. Weersing, I. Akkerman, E. Vellenga, and G. de Haan
Growth factor treatment prior to low-dose total body irradiation increases donor cell engraftment after bone marrow transplantation in mice
Blood, June 17, 2002; 100(1): 312 - 317.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. A. Velders, J. F. M. Pruijt, P. Verzaal, R. van Os, Y. van Kooyk, C. G. Figdor, E.-J. F. M. de Kruijf, R. Willemze, and W. E. Fibbe
Enhancement of G-CSF-induced stem cell mobilization by antibodies against the beta 2 integrins LFA-1 and Mac-1
Blood, June 17, 2002; 100(1): 327 - 333.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. F. M. Pruijt, P. Verzaal, R. van Os, E.-J. F. M. de Kruijf, M. L. J. van Schie, A. Mantovani, A. Vecchi, I. J. D. Lindley, R. Willemze, S. Starckx, et al.
Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice
PNAS, April 30, 2002; 99(9): 6228 - 6233.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
R. van Os, T. M. Sheridan, S. Robinson, D. Drukteinis, J. L.M. Ferrara, and P. M. Mauch
Immunogenicity of Ly5 (CD45)-Antigens Hampers Long-Term Engraftment Following Minimal Conditioning in a Murine Bone Marrow Transplantation Model
Stem Cells, January 1, 2001; 19(1): 80 - 87.
[Abstract] [Full Text]


Home page
Stem CellsHome page
S. Robinson, R. van Os, T. Sheridan, and P. Mauch
Reduction of Marrow Hematopoietic Progenitor and Stem Cell Content Is Not Sufficient for Enhanced Syngeneic Engraftment
Stem Cells, March 1, 2000; 18(2): 93 - 101.
[Abstract] [Full Text]


Home page
Stem CellsHome page
R. van Os, S. Robinson, T. Sheridan, and P. M. Mauch
Granulocyte-Colony Stimulating Factor Impedes Recovery from Damage Caused by Cytotoxic Agents through Increased Differentiation at the Expense of Self-Renewal
Stem Cells, March 1, 2000; 18(2): 120 - 127.
[Abstract] [Full Text]


Home page
BloodHome page
M. Rosenzweig, T.J. MacVittie, D. Harper, D. Hempel, R.L. Glickman, R.P. Johnson, A.M. Farese, N. Whiting-Theobald, G.F. Linton, G. Yamasaki, et al.
Efficient and Durable Gene Marking of Hematopoietic Progenitor Cells in Nonhuman Primates After Nonablative Conditioning
Blood, October 1, 1999; 94(7): 2271 - 2286.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
R. van Os, H. Avraham, N. Banu, P. M. Mauch, J. Whater, Y. Yang, and B. Du
Recombinant Adeno-Associated Virus-Based Vectors Provide Short-Term Rather Than Long-Term Transduction of Primitive Hematopoietic Stem Cells
Stem Cells, March 1, 1999; 17(2): 117 - 120.
[Abstract] [Full Text]


Home page
BloodHome page
R. van Os, S. Robinson, T. Sheridan, J. M.K. Mislow, D. Dawes, and P. M. Mauch
Granulocyte Colony-Stimulating Factor Enhances Bone Marrow Stem Cell Damage Caused by Repeated Administration of Cytotoxic Agents
Blood, September 15, 1998; 92(6): 1950 - 1956.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020